NurOwn Phase 2 results

Status
Not open for further replies.
And once again, " no significant difference in treated or untreated participants". Oh well, at least it won't kill you.

Vincent
 
however there were differences in the biomarkers that look hopeful. The dosing regimen in phase 3 is greater so only time will tell us if that translates to clinical effects but I think one could be cautiously optimistic
 
The reason they upped the dosing regimen in Phase 3 was to attempt to boost the signal seen in Phase 2. If there had been no signal, Phase 3 would not have been undertaken.

Also, the second interim safety analysis has identified no concerns with the heavier regimen, thus far.
 
Status
Not open for further replies.
Back
Top